NAMI HelpLine
Contents
I’m having a lot of anxiety because of the coronavirus. Please help.
I’m quarantined or working from home – lonely and isolated even further – what can I do?
I don’t have health insurance or a regular doctor – how can I get care?
What if I’m quarantin...ed and can’t get my medication? Will there be a shortage?
My business is suffering as a result of the Coronavirus. What assistance programs are available to help?
Are people who have a mental illness at a greater risk of contracting COVID-19?
Is there a vaccine or cure for COVID-19?
I lost a loved one to Coronavirus. Where can I find support?
I’m a smoker. Am I more likely to catch COVID-19? What should I do?
How does homelessness increase risk of contracting COVID-19?
My loved one is incarcerated, are they at increased risk for exposure to COVID-19?
I’m the aging parent of an adult child living with a serious mental illness. I want to be sure they are taken care of.
Are there any online support resources for people with substance use disorders?
more
In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood choles...terol.
In other areas, overtreatment can occur with the use of non-evidence-based
protocols. The aim of using standard treatment protocols is to improve the quality
of clinical care, reduce clinical variability and simplify the treatment options,
particularly in primary health care. Standard treatment protocols can be developed by preparing new national treatment guidelines or by adapting or adopting international guidelines.
The Evidence-based protocols module uses hypertension and diabetes screening
and treatment as an entry point to control cardiovascular risk factors, prevent target organ damage, and reduce premature morbidity and mortality. A comprehensive risk- based approach for integrated management of hypertension, diabetes, and high cholesterol is included in the Risk-based CVD management module.
This module includes clinical practice points and sample protocols for:
1. hypertension detection and treatment
2. type 2 diabetes detection and treatment
3. identifying basic emergencies – care and referral.
HEARTS emphasizes adaptation, dissemination, and use of a standardized set of
simple clinical-management protocols, which should be drug- and dose-specific,
and include a core set of medications. The simpler the protocols and management tools, the more likely they are to be used correctly, and the higher the likelihood that a programme will achieve its goals.
more
"This is the final report of the six-year collaboration between the WHO Department of Mental Health and Substance Abuse and the Gulbenkian Global Mental Health Platform, an initiative of the Calouste Gulbenkian Foundation aimed at reducing the global burden of mental health through the development a...nd application of evidence and good practices to global mental health."
more
The unmet need for palliative care in Cox’s Bazar
This is the first national Policy to combat AMR in Cambodia. It was developed based on conclusions and recommendations of a country situaytion analysis.
A practitioner’s guide to the principles of COVID-19 vaccine communications.
The factors that lead people to make choices to take vaccines are nuanced and affected by how they see the world, their perceptions of the choices people like them will make, who they trust, their perceptions of risk,... consistency of message and convenience of actually getting the vaccine.
more
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more